Overall Survival Benefit Up for Pyrotinib + Capecitabine in HER2-Positive Breast Cancer

THURSDAY, Nov. 16, 2023 (HealthDay News) -- For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, pyrotinib plus capecitabine offers an overall survival benefit, according to a study presented at the Advanced Breast Cancer Seventh International Consensus Conference, held from Nov. 9 to 11 in Lisbon, Portugal. Binghe Xu, M.D., from

Related Keywords

Portugal ,Peking ,Beijing ,China ,Lisbon ,Lisboa ,Shanghai ,Chinese ,Binghe Xu ,Fudan University Cancer Hospital ,Breast Cancer Seventh International Consensus Conference ,Union University ,Chinese Academy Of Medical Sciences ,Jiangsu Hengrui Pharmaceuticals ,Healthday News ,Chinese Academy ,Medical Sciences ,Peking Union University ,